ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) HKSE

6.69

+0.07(+1.06%)

Updated at December 05 04:09PM

Currency In HKD

Valuation

Market Cap1.83B
Enterprise Value1.49B
P/E Ratio-8.1
PEG Ratio-1.13
Price/Sales Ratio19.29
Price/Book Ratio4.58
Enterprise/Revenue17.24
Enterprise/EBITDA-7.04

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin-2.46
Operating Margin-2.53

Management Effectiveness

Return On Assets-0.39
Return On Equity-0.5

Income Statement

Revenue74.15M
Revenue/Share0.3
Gross Profit74.15M
EBITDA-295.63M
Net Income-315.86M
Diluted EPS-0.84

Balance Sheet

Total Cash703.7M
Total Cash/Share1
Total Debt153.72M
Total Debt/Equity0.29
Current Ratio3.33
Book Value Per Share1.31

Price History

52-Week Change9.41
52-Week High16.8
52-Week Low4.31
Moving Average 50 Days9.65
Moving Average 200 Days9.44

Statistics

Average Volume3.36M
Shares Outstanding393.69M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A